Insights

Strategic funding Laronde has secured substantial funding (490M total) including a 440M Series B, signaling strong investor confidence and a long runway. This suggests potential for partnerships that align with scale-up and manufacturing capabilities, as well as opportunities to co-develop or license eRNA platforms for broader disease areas.

Gigabase Factory The company aims to build a Gigabase Factory to support clinical and manufacturing operations. This indicates readiness for large-scale collaborations, contract development and manufacturing services, and potential for joint ventures to utilize their scalable eRNA platform.

Pipeline acceleration Rapid scaling to support multiple programs across disease areas points to opportunities for strategic alliances with biotech and pharma companies seeking diversified, parallel R&D pipelines and high-throughput collaboration models.

Co-development potential Recent partnership with Senda Biosciences and emphasis on programmable eRNA suggests open avenues for joint research agreements, data-sharing collaborations, and AI/biotech co-development deals leveraging their platform's delivery and expression capabilities.

Targeted outreach With a small team (11-50 employees) and heavy funding, Laronde may prioritize high-value collaborations with mid-to-large biopharma that require capability in RNA-based therapeutics, persistent expression, repeat dosing, and flexible formulation to expand into new therapeutic areas.

Similar companies to Laronde

Laronde Tech Stack

Laronde uses 8 technology products and services including RT-qPCR, GitHub, NoSQL, and more. Explore Laronde's tech stack below.

  • RT-qPCR
    Analytics
  • Communication And Collaboration
  • NoSQL
    Database
  • Database
  • Identity Verification
  • Microsoft Office
    Office Suites
  • Python
    Programming Languages
  • Flask
    Web Frameworks

Laronde's Email Address Formats

Laronde uses at least 2 email formats:
Laronde Email FormatsExamplePercentage
FLast@laronde.bioJDoe@laronde.bio
97%
First_Last@laronde.bioJohn_Doe@laronde.bio
3%

Frequently Asked Questions

What is Laronde's official website and social media links?

Minus sign iconPlus sign icon
Laronde's official website is laronde.bio and has social profiles on LinkedIn and Crunchbase.

How much revenue does Laronde generate?

Minus sign iconPlus sign icon
As of October 2026, Laronde's annual revenue is estimated to be $1M - $10M.

What is Laronde's SIC code and NAICS code?

Minus sign iconPlus sign icon
Laronde's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Laronde have currently?

Minus sign iconPlus sign icon
As of October 2026, Laronde has approximately 44 employees across 3 continents, including North America, Asia and Europe. Key team members include Research Associate Ii: A. J., Caissier Service Clients: N. S. and Restaurant: H. D. Explore Laronde's employee directory with LeadIQ.

What industry does Laronde belong to?

Minus sign iconPlus sign icon
Laronde operates in the Biotechnology Research industry.

What technology does Laronde use?

Minus sign iconPlus sign icon
Laronde's tech stack includes RT-qPCR, GitHub, NoSQL, PostgreSQL, Okta, Microsoft Office, Python and Flask.

What is Laronde's email format?

Minus sign iconPlus sign icon
Laronde's email format typically follows the pattern of FLast@laronde.bio. Find more Laronde email formats with LeadIQ.

How much funding has Laronde raised to date?

Minus sign iconPlus sign icon
As of October 2026, Laronde has raised $490M in funding. The last funding round occurred on Aug 30, 2021 for $440M.

When was Laronde founded?

Minus sign iconPlus sign icon
Laronde was founded in 2017.
Laronde logo

Laronde

Biotechnology ResearchMassachusetts, United States11-50 Employees

Laronde is a biotechnology research company focused on expanding the boundaries of human biology through a programmable RNA platform. Its Endless RNA (eRNA) technology can be directed to produce diverse proteins within the body, with characteristics described as persistent, non-immunogenic, and capable of supporting repeat dosing, while offering flexibility in how it is formulated and delivered. The business was founded in 2017 by Flagship Labs, the innovation arm of Flagship Pioneering, and is headquartered in Cambridge, Massachusetts. The organization is scaling to advance multiple therapeutic programs across a range of disease areas.

It operates within the biotechnology sector, positioning itself as a platform company that aims to enable new approaches to treating disease. By enabling programmable protein expression inside the body, the technology is intended to support development of therapies across diverse indications, potentially appealing to biopharmaceutical developers seeking novel modalities. In October 2023, Laronde announced a collaboration with Senda Biosciences, reflecting ongoing efforts to broaden its research and development footprint.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
11-50

Section iconFunding & Financials

  • $490M

    Laronde has raised a total of $490M of funding over 2 rounds. Their latest funding round was raised on Aug 30, 2021 in the amount of $440M as a Series B.

  • $1M - $10M

    Laronde's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.